Abstract
Background: Rituximab is considered a therapeutic option in children with refractory nephrotic syndrome (RNS). However, the efficacy and safety of rituximab treatment remain unclear. Objective: This study systematically evaluated the clinical effectiveness and related adverse event profiles of rituximab compared with other immunosuppressants in children with RNS. Method: Two independent investigators conducted the methodological rigor evaluation in a double-blind manner. Statistical analyses were performed using RevMan 5.4. Results: Relative to other conventional second-line agents, rituximab therapy presented a significantly increased relapse-free survival rate [vs. tacrolimus: OR = 3.42, 95% CI = 1.96–5.94, P < 0.01]. Fewer adverse drug reactions occurred in patients with rituximab than with other immunosuppressants [vs. cyclophosphamide: OR = 0.18, 95% CI = 0.04–0.89, P = 0.03; vs. tacrolimus: OR = 0.26, 95% CI = 0.07–0.92, P = 0.04]. The application of rituximab increased the steroid-discontinued rate and decreased the corticosteroid dose in the treatment [vs. cyclophosphamide: OR = 5.46, 95% CI = 2.00–14.92, P = 0.0009; vs. tacrolimus: OR = 3.42, 95% CI = 1.67–7.01, P = 0.0008]. Conclusion: Our study demonstrates rituximab’s superior efficacy and safety profile compared to conventional second-line immunosuppressants in pediatric RNS, particularly regarding steroid minimization. Systematic review registration number: CRD420251082051. Graphical

This publication has 37 references indexed in Scilit: